咨询订购

点击这里给我发消息
Welcome to Raystarbio!Focus On Forefront Bioactive Compounds.
Find Your Distributors

Select Your Country or Region

$ USD

You are here:Home-Research Areas-Cardiovascular Disease-Dyslipidemia

Request The Product List ofDyslipidemia Dyslipidemia

    Dyslipidemia is a medical condition that refers to an abnormal level of blood lipids. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation of insulin levels can also lead to dyslipidemia. Likewise, increased levels of O-GlcNAc transferase (OGT) may cause dyslipidemia.

   The most common type of dyslipidemia is hyperlipidemia or high lipid levels. Another, less common form of dyslipidemia, hypolipidemia, refers to lipid levels that are abnormally low. Dyslipidemias can affect any lipid parameter, including LDL cholesterol levels, HDL cholesterol levels, triglycerides, or a combination of these lipids.

   Healthy blood lipid levels naturally vary from person to person. However, people with high levels of LDL and triglycerides or very low HDL levels tend to have a higher risk of developing atherosclerosis.

   Atherosclerosis develops when hard, fatty deposits called plaques accumulate in blood vessels, making it difficult for blood to flow.

   Over time, these plaques can build up and cause major circulation problems, such as heart attacks and strokes.



Cat. No. Product Name CAS No. Information
GY03981

BMS-687453

1000998-59-3

A potent and selective PPARα agonist with EC50 of 10 nM for human PPARα and 410-fold selectivity over human PPARγ in PPAR-GAL4 transactivation assays; has negligible cross-reactivity against a panel of human nuclear hormone receptors including PPARδ; demonstrates an excellent pharmacological and safety profile for the treatment of atherosclerosis and dyslipidemia.

GY02908

Ro 48-8071 fumarate

189197-69-1

A potent 2,3-oxidosqualene cyclase (OSC) inhibitor with IC50 of 6.5 nM; 6 times less potent against hamster and Gottingen minipig liver OSC, and 10-times more potent against squirrel monkey liver OSC; blocks human liver OSC and cholesterol synthesis in HepG2 cells in the nanomolar range; triggers the production of monooxidosqualene, dioxidosqualene, and epoxycholesterol.

GY02704

Ro 48-8071

161582-11-2

A potent 2,3-oxidosqualene cyclase (OSC) inhibitor with IC50 of 6.5 nM; 6 times less potent against hamster and Gottingen minipig liver OSC, and 10-times more potent against squirrel monkey liver OSC; blocks human liver OSC and cholesterol synthesis in HepG2 cells in the nanomolar range; triggers the production of monooxidosqualene, dioxidosqualene, and epoxycholesterol.

GY07083

LY-2562175

1103500-20-4

LY-2562175 (LY2562175, LY 2562175) is a novel potent, selective, partial FXR agonist with EC50 of 193 nM; does not promote transcriptional activation of other nuclear receptor, such as GR, PR, MR and AR (EC50>10 uM); lowers LDL and triglycerides while raising HDL in preclinical species.

GY03787

Seladelpar

851528-79-5

A potent, selective, orally bioavailable PPARδ agonist for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH).

GY04308

Laropiprant

571170-77-9

Laropiprant is a potent and selective prostaglandin D2 (PGD2) receptor (DP1) antagonist with Ki of 0.57 nM; shows weaker affinity for TP (Ki=2.95 nM), no significant activity on EP1, EP2, EP3, EP4, FP, and IP; inhibits the accumulation of cAMP in washed platelets and in plateletrich plasma challenged with PGD with IC50 of 0.09 nM and 4 nM, respectively; displays an excellent rat pharmacokinetic profile and efficacious in a sheep model of allergic rhinitis.

GY04265

GW501516

317318-70-0

GW501516 is a potent and subtype-selective PPARδ agonist with Ki of 1.1 nM in human PPARδ binding assay; displays >1,000-fold selectivity over other PPAR subtypes; increases expression of the reverse cholesterol transporter ATP-binding cassette A1 and induces apolipoprotein A1-specific cholesterol efflux in macrophages, fibroblasts, and intestinal cells.

GY01562

Avasimibe

166518-60-1

Avasimibe (CI-1011, PD-148515) is a potent, selective inhibitor of acyl-CoA: cholesterol O-acyl transferase (ACAT) with IC50 of 60 nM; potently reduces plasma cholesterol in chow-fed rats and in rabbits fed a cholesterol-free, casein-containing diet characterized by both hepatic overproduction of apo B-containing lipoproteins and delayed lipoprotein clearance; decreases both VLDL and LDL apolipoprotein B production in miniature pigs; synergistically reduces cholesteryl ester content in THP-1 macrophages combined with Atorvastatin,

GY05699

Pemafibrate

848259-27-8

Pemafibrate (K-877) is a highly potent, specific PPARα agonist with EC50 of 1 nM; displays >2,000-fold selectivity for PPARα over others subtypes in a CHO cell-based transactivation assay; upregulates the expression of several fatty acid β-oxidative genes in human hepatocytes and the mouse liver; significantly induces the expression of clinically beneficial target genes (VLDLR, FGF21, ABCA1, MBL2, ENPEP) in human hepatocytes.

GY05565

TAP-311

1149362-88-8

TAP-311(TAP311) is a novel potent and selective CETP inhibitor with plasma IC50 of 62 nM; displays >170-fold selectivity over CYPs, and has excellent pharmacokinetics in rats and robust efficacy in hamsters; shows substantially reduced lipophilicity with only modest distribution into adipose tissue, and retains potency in hypertriglyceridemic plasma in vitro and in vivo; does not increase blood pressure or plasma aldosterone levels in vivo, in contrast to torcetrapib.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 RayStarBio. All Rights Reserved. Products are only for research use